HighTower Advisors LLC increased its position in Smith & Nephew plc (NYSE:SNN) by 42.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,889 shares of the medical equipment provider’s stock after purchasing an additional 15,670 shares during the period. HighTower Advisors LLC’s holdings in Smith & Nephew were worth $1,893,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. WCM Investment Management LLC lifted its holdings in Smith & Nephew by 57.0% in the first quarter. WCM Investment Management LLC now owns 6,585,160 shares of the medical equipment provider’s stock worth $236,210,000 after acquiring an additional 2,389,692 shares during the last quarter. Nuance Investments LLC lifted its holdings in Smith & Nephew by 104.7% in the fourth quarter. Nuance Investments LLC now owns 3,316,821 shares of the medical equipment provider’s stock worth $159,440,000 after acquiring an additional 1,696,272 shares during the last quarter. BlackRock Inc. lifted its holdings in Smith & Nephew by 18,404.8% in the first quarter. BlackRock Inc. now owns 1,370,283 shares of the medical equipment provider’s stock worth $49,152,000 after acquiring an additional 1,362,878 shares during the last quarter. FMR LLC lifted its holdings in Smith & Nephew by 640.8% in the first quarter. FMR LLC now owns 1,341,034 shares of the medical equipment provider’s stock worth $53,788,000 after acquiring an additional 1,160,015 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in Smith & Nephew by 163.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 673,103 shares of the medical equipment provider’s stock worth $32,357,000 after acquiring an additional 417,328 shares during the last quarter. Institutional investors and hedge funds own 9.45% of the company’s stock.

SNN has been the topic of a number of recent research reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew in a report on Thursday, May 7th. Berenberg Bank reissued a “buy” rating on shares of Smith & Nephew in a report on Monday, May 11th. BNP Paribas cut shares of Smith & Nephew from a “neutral” rating to an “underperform” rating in a report on Friday, June 5th. Morgan Stanley raised Smith & Nephew from an “equal weight” rating to an “overweight” rating in a report on Thursday, June 4th. Finally, Zacks Investment Research raised Smith & Nephew from a “sell” rating to a “hold” rating in a report on Tuesday, June 2nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $48.00.

SNN opened at $37.89 on Tuesday. The business’s 50 day moving average is $40.64 and its 200-day moving average is $42.75. The stock has a market cap of $16.47 billion, a PE ratio of 18.57, a price-to-earnings-growth ratio of 6.06 and a beta of 0.58. The company has a current ratio of 2.06, a quick ratio of 1.03 and a debt-to-equity ratio of 0.38. Smith & Nephew plc has a twelve month low of $26.07 and a twelve month high of $52.26.

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Featured Story: What is the Russell 2000 Index?

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN).

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.